Clarient to Purchase Applied Genomics for Nearly $18M | GenomeWeb

NEW YORK (GenomeWeb News) – Healthcare technology services provider Clarient announced after the close of the market Monday that it will acquire the Huntsville, Ala.-based cancer molecular diagnostics company Applied Genomics.

The all-stock merger is valued at up to $17.6 million, "if all conditions and milestones set forth in the merger agreement are successfully met." Applied Genomics will become a wholly-owned subsidiary of Clarient.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: map of UV-induced damage in yeast genome, comparative epigenomics uncovers plant lacking key DNA methyltransferase enzyme, and more.

Researchers kick off their second Queer in STEM survey to examine what can make STEM careers welcoming, Wired reports.

A startup company is offering a test to analyze soil samples from farms for pathogens.

Prosecutors seek to introduce evidence from low-template DNA analysis in a murder case in upstate New York, the New York Times reports.